

STI/HIV Quarterly Report

San Mateo County (SMC) Health, STI/HIV Program

<https://www.smchealth.org/hivstds> · STI Clinic: 650.573.2385 · Provider STI Reporting: 650.573.2346 650.573.2919 (fax)
Issue No. 72 · Quarter 2: Apr 1 - Jun 30, 2024

Vivian Levy MD, STI Controller · Kismet Baldwin-Santana MD, MPH, Health Officer · Asa Ohsaki, MPH Epidemiologist

Table 1 STI Cases Reported Among County of San Mateo Residents by Quarter (Apr 1 - Jun 30) and Year to Date for 2024 and 2023

		2024		2023	
		2nd Qtr	YTD ¹	2nd Qtr	YTD
Chlamydia trachomatis (CT)	Total	646	1,226	672	1,369
	Male	262	513	308	640
	Female	383	710	363	722
	Transgender/Other/Unknown ²	1	3	1	7
Gonorrhea (GC)	Total	185	368	236	483
	Male	157	313	184	380
	Female	26	51	49	96
	Transgender/Other/Unknown	2	4	3	7
GC Clinical Site³	Urine	97	179	109	209
	Genitourinary	9	19	26	57
	Rectal	49	97	62	132
	Pharyngeal	68	129	80	172
	Unknown/Missing	0	0	0	0
	DGI ⁴	0	0	0	0
Early Syphilis⁵	Total	22	43	48	92
	Male	20	37	36	72
	Female	1	4	11	18
	Transgender/Other/Unknown	1	2	1	2
Late Syphilis	Total	30	62	32	71
	Male	18	38	22	48
	Female	12	22	10	22
	Transgender/Other/Unknown	0	2	0	1
Syphilis by Stage	Primary	5	13	9	17
	Secondary	4	8	12	24
	Early Latent	13	22	27	51
	Late Latent	30	62	32	71
	Congenital	0	0	0	0
	Neurosyphilis ⁶	0	2	2	3
Mpox	Total	3	8	2	8

¹YTD: Year to Date. ²Due to data limitations and confidentiality concerns, transgender women, transgender men, and gender diverse persons are combined ³Clinical sites for gonorrhea are non-exclusive (individual patient may have multiple sites tested). ⁴Disseminated Gonococcal Infection. ⁵Early Syphilis is defined as primary, secondary, and early latent. ⁶Cases not included in the total as neurosyphilis is a sequelae and not a stage; the neurosyphilis cases are captured under other syphilis stages.

- Early syphilis decreased by 53% and late syphilis decreased by 13% compared to this time last year. 4 early syphilis cases were female (9%) compared to 18 in 2023 (20%). 22 late latent syphilis cases were female in both 2024 (35%) and 2023 (31%).
- CT decreased 20% in men and 2% in women compared to this time last year. GC decreased 17% in men and 47% in women compared to last year.
- Specimens tested for HIV increased 5% compared to last year. To date in 2024, HIV positive prevalence is higher than 2023 (0.9% versus 0.8%).

Table 2 HIV testing through the San Mateo County Health System by Quarter (Apr 1 - Jun 30) and Year to Date for 2024 and 2023¹

		2024		2023	
		2nd Qtr	YTD	2nd Qtr	YTD
Total Specimens Tested for HIV		2,758	5,436	2,625	5,166
SMC-STI Clinic		22	42	50	97
STI/HIV Program Outreach ²		217	370	113	169
Other County Clinics ³		2,519	5,024	2,462	4,900
Total HIV Antibody Positive		24	50	22	43
SMC-STI Clinic		1	2	0	1
STI/HIV Program Outreach ²		0	0	1	1
Other County Clinics ³		23	48	21	41
Total New HIV Cases		5	11	5	10

¹The HIV antibody positives do not reflect the true burden of disease. Some patients may be repeat testers. ²Testing-on-Demand and STI/HIV Program HIV Rapid Tests. ³Includes all HIV testing (oral and blood) at San Mateo Medical Center (SMMC), SMMC Satellite Clinics, SMC Public Health (PH) Clinics, and PH Subcontractors. Beginning Aug 2015, a 4th generation HIV screening test was implemented. HIV positive cases may not yet be confirmed by HIV-1/HIV-2 differentiation immunoassay.

Mpox clade I in Africa

CDC considers US mpox clade I risk very low



- On Aug 7, 2024, CDC issued a health alert on [spread of mpox clade I in Democratic Republic of Congo & other African countries](#). Mpox clade I is associated with higher transmissibility & more severe disease than clade IIb which caused the 2022 US outbreak.
- [World Health Organization](#) declared mpox clade I a public health emergency of international concern. CDC considers the risk of clade I mpox to the US general population to be low.
- US clinicians should obtain a travel history on all suspected patients with mpox.
- If [clade I mpox infection is suspected](#) due to recent travel to Africa or close contact with person returned from Africa within 21 days prior to contact, providers should immediately notify the SMC STI Officer of the Day at (650)573-2346 and send specimens to the California Department of Public Health (CDPH) Viral and Rickettsial Disease Laboratory (VRDL) for expedited clade specific mpox testing.
- Since the 2-dose Jynneos vaccine is anticipated to be effective against mpox clade I, [providers](#) are encouraged to vaccinate [persons at risk](#) or those who request the vaccine.

Bicillin L-A Shortage Over

- Long-acting benzathine penicillin G (Bicillin® L-A) is [now available](#) and should be used to treat all primary, secondary, and latent syphilis cases in adults and adolescents.